Why do we Still Use 5-ASAs in Crohn's Disease?

Stephen B. Hanauer*, Henit Yanai, Emma Calabrese

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Over the past two decades there has been an expanding database regarding the role of aminosalicylates for the treatment of Crohn's disease (CD). While initial evidence demonstrated a small, but clinically significant benefit for sulfasalazine in mild-moderate CD and the initial experience with mesalamine formulations was positive; evolving data from large, follow-up Phase III and investigator-initiated trials in active disease and in postoperative disease have been less supportive of an overall role. Nevertheless, there continues to be clinical support for treatment of mild, inflammatory CD with aminosalicylates and for maintaining 5-ASA induced remissions in responding patients.

Original languageEnglish
Title of host publicationClinical Dilemmas in Inflammatory Bowel Disease
Subtitle of host publicationNew Challenges: Second Edition
Number of pages4
ISBN (Print)9781444334548
StatePublished - 30 Jan 2012
Externally publishedYes


  • Aminosalicylates
  • Crohn's disease
  • Medical therapy
  • Mesalamine
  • Mesalazine
  • Sulfasalazine


Dive into the research topics of 'Why do we Still Use 5-ASAs in Crohn's Disease?'. Together they form a unique fingerprint.

Cite this